EP3269733A4 - Peptid aus gpc3, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs damit, immunitätsinduzierer und verfahren zur herstellung von antigenhaltigen zellen - Google Patents

Peptid aus gpc3, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs damit, immunitätsinduzierer und verfahren zur herstellung von antigenhaltigen zellen Download PDF

Info

Publication number
EP3269733A4
EP3269733A4 EP16761783.6A EP16761783A EP3269733A4 EP 3269733 A4 EP3269733 A4 EP 3269733A4 EP 16761783 A EP16761783 A EP 16761783A EP 3269733 A4 EP3269733 A4 EP 3269733A4
Authority
EP
European Patent Office
Prior art keywords
gpc3
cancer
prevention
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16761783.6A
Other languages
English (en)
French (fr)
Other versions
EP3269733A1 (de
EP3269733B1 (de
Inventor
Tomoya Miyakawa
Masaaki Oka
Shoichi HAZAMA
Koji Tamada
Keiko Udaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytlimic Inc
Original Assignee
Cytlimic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytlimic Inc filed Critical Cytlimic Inc
Publication of EP3269733A1 publication Critical patent/EP3269733A1/de
Publication of EP3269733A4 publication Critical patent/EP3269733A4/de
Application granted granted Critical
Publication of EP3269733B1 publication Critical patent/EP3269733B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP16761783.6A 2015-03-09 2016-03-09 Peptid aus gpc3, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs damit, immunitätsinduzierer und verfahren zur herstellung von antigenhaltigen zellen Active EP3269733B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015046463 2015-03-09
PCT/JP2016/057356 WO2016143816A1 (ja) 2015-03-09 2016-03-09 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法

Publications (3)

Publication Number Publication Date
EP3269733A1 EP3269733A1 (de) 2018-01-17
EP3269733A4 true EP3269733A4 (de) 2018-08-01
EP3269733B1 EP3269733B1 (de) 2020-06-17

Family

ID=56880605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16761783.6A Active EP3269733B1 (de) 2015-03-09 2016-03-09 Peptid aus gpc3, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs damit, immunitätsinduzierer und verfahren zur herstellung von antigenhaltigen zellen

Country Status (12)

Country Link
US (3) US10526388B2 (de)
EP (1) EP3269733B1 (de)
JP (1) JP6898225B2 (de)
CN (2) CN107428815B (de)
AU (1) AU2016230125B2 (de)
BR (1) BR112017018703A2 (de)
CA (1) CA2979168A1 (de)
DK (1) DK3269733T3 (de)
ES (1) ES2805829T3 (de)
RU (1) RU2714117C2 (de)
TW (2) TW202115102A (de)
WO (1) WO2016143816A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
ES2882827T3 (es) 2014-10-07 2021-12-02 Cytlimic Inc Péptido inductor de inmunidad derivado de HSP70
BR112017018703A2 (pt) 2015-03-09 2018-04-17 Cytlimic Inc. peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
JP6311094B2 (ja) 2015-04-07 2018-04-18 サイトリミック株式会社 医薬
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
KR102211985B1 (ko) * 2019-05-02 2021-02-05 주식회사 엘베이스 신규한 올리고펩티드 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2023163094A1 (ja) 2022-02-25 2023-08-31 日本電気株式会社 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
EP0893507A1 (de) 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
CN1555272A (zh) 2001-07-31 2004-12-15 �ո��� 调节免疫应答的组合物和方法
AU2003254950A1 (en) * 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
JP2006512391A (ja) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
EA200702254A1 (ru) 2005-05-19 2008-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцинная композиция, содержащая в-субъединицу термолабильного токсина e.coli и антиген и адъювант
JP5299942B2 (ja) * 2005-08-09 2013-09-25 オンコセラピー・サイエンス株式会社 ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬
US20100015101A1 (en) 2006-03-28 2010-01-21 Noriyuki Sato Novel tumor antigen peptides
RU2333767C2 (ru) 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
CN102850433B (zh) 2006-10-17 2016-03-02 肿瘤疗法科学股份有限公司 用于表达mphosph1或depdc1多肽的癌症的肽疫苗
US20100137221A1 (en) 2007-02-27 2010-06-03 University Utah Research Foundation Peptides that interact with topoisomerase i and methods thereof
JP2010538655A (ja) 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
JP5796014B2 (ja) 2009-10-06 2015-10-21 パナセラ ラブス， インコーポレイテッド がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用
MX2014009285A (es) 2012-02-07 2015-02-04 Jolla Inst Allergy Immunolog Alergenos del fleo de los prados y metodos y usos para la modulacion de respuesta inmune.
US20130217122A1 (en) * 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en) 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
SG11201506727RA (en) 2013-03-01 2015-09-29 Astex Pharmaceuticals Inc Drug combinations
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
ES2882827T3 (es) 2014-10-07 2021-12-02 Cytlimic Inc Péptido inductor de inmunidad derivado de HSP70
BR112017018703A2 (pt) 2015-03-09 2018-04-17 Cytlimic Inc. peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
JP6311094B2 (ja) 2015-04-07 2018-04-18 サイトリミック株式会社 医薬
US11291718B2 (en) * 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
RU2017135038A (ru) 2019-04-08
US10526388B2 (en) 2020-01-07
US20180105567A1 (en) 2018-04-19
TWI714558B (zh) 2021-01-01
CN113388021A (zh) 2021-09-14
ES2805829T3 (es) 2021-02-15
US20200157163A1 (en) 2020-05-21
US20190062389A1 (en) 2019-02-28
CA2979168A1 (en) 2016-09-15
CN107428815B (zh) 2021-07-09
BR112017018703A2 (pt) 2018-04-17
AU2016230125A1 (en) 2017-09-21
AU2016230125B2 (en) 2020-07-16
DK3269733T3 (da) 2020-07-27
EP3269733A1 (de) 2018-01-17
RU2714117C2 (ru) 2020-02-11
TW202115102A (zh) 2021-04-16
US10590179B2 (en) 2020-03-17
JP6898225B2 (ja) 2021-07-07
CN107428815A (zh) 2017-12-01
RU2017135038A3 (de) 2019-08-30
JPWO2016143816A1 (ja) 2018-03-01
WO2016143816A1 (ja) 2016-09-15
US10875900B2 (en) 2020-12-29
EP3269733B1 (de) 2020-06-17
TW201639869A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
EP3269733A4 (de) Peptid aus gpc3, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs damit, immunitätsinduzierer und verfahren zur herstellung von antigenhaltigen zellen
EP3368559A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3541386A4 (de) Zusammensetzungen und verfahren zur behandlung von opioidüberdosierung
EP3544679A4 (de) Systeme und verfahren zur ästhetischen behandlung
EP3320093A4 (de) Zusammensetzungen und verfahren zur identifizierung, beurteilung, vorbeugung und behandlung von krebs mithilfe von slncr-isoformen
EP3630089A4 (de) Verfahren für eine krebstherapie
EP3245225A4 (de) Zusammensetzungen und verfahren zur behandlung und detektion von krebs
EP3094352A4 (de) Zusammensetzungen und verfahren zur behandlung und zum nachweis von krebs
EP3800248A3 (de) Crispr-cas-assoziierte verfahren, zusammensetzungen und komponenten für krebsimmuntherapie
EP3519833A4 (de) Verfahren zur prognose und behandlung
EP3258966A4 (de) Verfahren, zusammensetzungen und kits zur behandlung von krebs
EP3195866A4 (de) Pharmazeutische zusammensetzung zur behandlung von flt3-mutationspositivem krebs, flt3-mutanter inhibitor und verwendung dieser pharmazeutischen zusammensetzung und dieses inhibitors
EP3554502A4 (de) Verfahren zur behandlung von cochlea-synaptopathie
EP3353204A4 (de) Verfahren und zusammensetzungen für die behandlung von krebs
EP3253384A4 (de) Mebendazol-polymorph zur behandlung und vorbeugung von tumoren
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP3446749A4 (de) Heissplasmakrankheitbehandlungssystem und verfahren zur verwendung davon
EP3471722A4 (de) Verbindungen, zusammensetzungen und verfahren zur prävention und/oder behandlung von krebs
EP3178491A4 (de) Zusammensetzung zur verbesserung der induktion von humoraler immunität und pharmazeutische impfstoff zusammensetzung
EP3368034A4 (de) Verfahren und zusammensetzungen zur behandlung von kopf-hals-karzinom
EP3307301A4 (de) Fokussierte interferonimmuntherapie zur behandlung von krebs
EP3328372A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3205661A4 (de) Hsp70-deriviertes peptid und verfahren zur herstellung einer pharmazeutischen zusammensetzung, immunitätsinduzierer und antigen-präsentierende zellen zur krebsbehandlung oder vorbeugung damit
EP3185910A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP3302458A4 (de) Verfahren zur prävention und behandlung von autoimmunität

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180703

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0786 20100101ALI20180627BHEP

Ipc: C07K 14/705 20060101AFI20180627BHEP

Ipc: A61P 37/04 20060101ALI20180627BHEP

Ipc: A61K 38/00 20060101ALI20180627BHEP

Ipc: A61K 39/00 20060101ALI20180627BHEP

Ipc: A61P 35/00 20060101ALI20180627BHEP

Ipc: C12N 5/0784 20100101ALI20180627BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190412

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200306

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016038290

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1281183

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200715

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200720

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200918

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200917

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200917

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1281183

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201019

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2805829

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201017

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016038290

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20210318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210309

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210309

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602016038290

Country of ref document: DE

Owner name: NEC CORPORATION, JP

Free format text: FORMER OWNER: CYTLIMIC INC., TOKYO, JP

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20230119 AND 20230125

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: NEC CORPORATION; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: CYTLIMIC INC.

Effective date: 20230123

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: NEC CORPORATION

Effective date: 20230310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240320

Year of fee payment: 9

Ref country code: GB

Payment date: 20240320

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240329

Year of fee payment: 9

Ref country code: FR

Payment date: 20240328

Year of fee payment: 9

Ref country code: DK

Payment date: 20240326

Year of fee payment: 9

Ref country code: BE

Payment date: 20240320

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240401

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240429

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200617